Skip to main content

Modelling immunization strategies with cytomegalovirus vaccine candidates

  • R. S. AZEVEDO (a1) and M. AMAKU (a2)

In order to analyse the impact of vaccination against cytomegalovirus (CMV) on congenital infection incidence using current vaccines tested in phase II clinical trials, we simulated different scenarios by mathematical modelling, departing from the current vaccine characteristics, varying age at vaccination, immunity waning, vaccine efficacy and mixing patterns. Our results indicated that the optimal age for a single vaccination interval is from 2 to 6 months if there is no immunity waning. Congenital infection may increase if vaccine-induced immunity wanes before 20 years. Congenital disease should increase further when the mixing pattern includes transmission among children with a short duration of protection vaccine. Thus, the best vaccination strategy is a combined schedule: before age 1 year plus a second dose at 10–11 years. For CMV vaccines with low efficacy, such as the current ones, universal vaccination against CMV should be considered for infants and teenagers.

Corresponding author
*Author for correspondence: Professor R. S. Azevedo, Departamento de Patologia, Avenida Doutor Arnaldo 455, São Paulo, SP, 01246-903, Brazil. (Email:
Hide All
1.Almeida LNB, et al. Cytomegalovirus seroepidemiology in an urban community of São Paulo, Brazil. Revista de Saude Publica 2001; 35: 124129.
2.Fang FQ, et al. Incidence of cytomegalovirus infection in Shanghai, China. Clinical and Vaccine Immunology 2009; 16: 17001703.
3.Coonrod D, et al. Association between cytomegalovirus seroconversion and upper genital tract infection among women attending a sexually transmitted disease clinic: a prospective study. Journal of Infectious Diseases 1998; 177: 11881193.
4.Plotkin SA. Congenital cytomegalovirus infection and its prevention. Clinical Infectious Diseases 2004; 38: 10381039.
5.Porath A, et al. Effectiveness and cost benefit of a proposed live cytomegalovirus vaccine in the prevention of congenital disease. Reviews of Infectious Diseases 1990; 12: 3140.
6.Pass RF, et al. Vaccine prevention of maternal cytomegalovirus infection. New England Journal of Medicine 2009; 360: 11911199.
7.Griffiths PD, McLean A, Emery VC. Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine 2001; 19: 13561362.
8.Amaku M, et al. Vaccination against rubella: Analysis of the temporal evolution of the agedependent force of infection and the effects of different contact patterns. Physical Reviews E 2003; 67: 051907.
9.Amaku M, Azevedo RS. Estimating the true incidence of rubella. Mathematical Population Studies 2010; 17: 91–100.
10.Fernandes GCVR, et al. Seroepidemiology of Toxoplasma infection in a metropolitan region of Brazil. Epidemiology and Infection 2009; 137: 18091815.
11.Plotkin SA. Cytomegalovirus vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Philadelphia: Saunders Elsevier, 2008, pp. 11471154.
12.Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-live. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Philadelphia: Saunders Elsevier, 2008, pp. 631685.
13.Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Reviews in Medical Virology 2007; 17: 253276.
14.WHO Executive Board. 2009 Global Elimination of Measles Report EB125/4 ( Accessed 2 March 2010.
15.Farrington CP. Modelling forces of infection for measles, mumps and rubella. Statistics in Medicine 1990; 9: 953967.
16.Lübeck PR, Doerr HW, Rabenau HF. Epidemiology of human cytomegalovirus (HCMV) in an urban region of Germany: what has changed? Medical Microbiology and Immunology 2010; 199: 5360.
17.Cui X, et al. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 2008; 26: 57605766.
18.Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. Journal of the American Medical Association 2003; 289: 10081011.
19.Yamamoto AY, et al. Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. American Journal of Obstetrics and Gynecology 2010; 202: 297.e1–8.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Full text views

Total number of HTML views: 1
Total number of PDF views: 10 *
Loading metrics...

Abstract views

Total abstract views: 79 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 24th November 2017. This data will be updated every 24 hours.